Ironwood Pharmaceuticals, Inc.'s (IRWD) CEO Mark Mallon on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/09/20
Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 MillionBusiness Wire • 08/06/20
Ironwood Pharmaceuticals (IRWD) Reports Next Week: What You Should ExpectZacks Investment Research • 07/30/20
Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD)Business Wire • 07/21/20
Ironwood Pharmaceuticals (IRWD) Looks Good: Stock Adds 7.6% in SessionZacks Investment Research • 06/03/20
Ironwood Pharmaceuticals, Inc. (IRWD) CEO Peter Ingram on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/07/20
Ironwood Pharmaceuticals (IRWD) Misses Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/06/20
Ironwood (IRWD) Down 22.1% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/14/20
Ironwood Pharmaceuticals, Inc. (IRWD) CEO Mark Mallon on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/13/20
Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Beat EstimatesZacks Investment Research • 02/13/20
Are You Looking for a Top Momentum Pick? Why Ironwood Pharmaceuticals (IRWD) is a Great ChoiceZacks Investment Research • 12/27/19
Is Ironwood Pharmaceuticals (IRWD) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 12/25/19